Exiqon to Buy Cancer Test Provider Oncotech For $45M to Speed Entry Into miRNA Dx Field

With the addition of Oncotech’s expertise and resources in molecular oncology testing, Exiqon now expects to introduce its first microRNA-based diagnostic to the US market before the end of 2008. The buy also sets up the Danish company to be the first real competitor to Rosetta Genomics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.